BIO-AST Biologics for chronic severe asthma: a network meta-analysis
Crossingham I., Richardson R., Hinks TSC., Spencer S., Couillard S., Maynard-Paquette AC., Thomassen D., Howell I.
Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To evaluate the benefits and harms of biological agents targeting type-2 inflammation (benralizumab, dupilumab, mepolizumab, omalizumab, reslizumab, tezepelumab) in people with severe asthma, with a network meta-analysis and to rank agents by effectiveness.